|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Because of the widespread distribution of NPY, it has been implicated in the modulation of a variety of behaviors, including, but not limited to, circadian rhythms /1/, memory retention /33/, feeding /19,56/, sympathetic control of cardiovascular function /89/ and anxiety /42,43/.
|
9711903 |
1998 |
|
Anxiety Disorders
|
0.400 |
Therapeutic
|
group |
CTD_human |
The Y1 receptor antagonist blocked the anxiolytic-like effect of neuropeptide Y, while the Y2 receptor antagonist was ineffective.We conclude that neuropeptide Y in the dorsocaudal lateral septum may act as an endogenous anxiolytic and antagonize corticotropin-releasing hormone (stress)-induced anxiety.
|
11440811 |
2001 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings point to the potential of the NPY system for developing novel pharmacological treatments of stress-related disorders, including anxiety and depression.
|
12013027 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Following recovery, a test of anxiety was conducted in which the rats (n = 12-13/group) received either artificial cerebrospinal fluid (aCSF) or NPY (10 microg) 10 min prior to a 5-min test on an elevated plus maze.
|
12824809 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
I also suggest that, via CREB, NPY might interact with other CREB target genes, such as the gene encoding brain-derived neurotrophic factor, and that this CREB-mediated interaction might be important in the regulation of anxiety and alcohol drinking behaviors.
|
12967770 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Extensive animal studies suggest neuropeptide Y (NPY) to be involved in coping with a wide range of stressors, and that impaired central NPY signalling could be involved in the pathophysiology of anxiety and depression.
|
14757324 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We found correspondence between linkage and microarray/candidate gene studies for genes involved with the mitogen-activated protein kinase (MAPK) signaling system, nuclear factor kappa B (NFKB) complex, neuropeptide Y (NPY) neurotransmission, a nicotinic receptor subunit (CHRNA2), the vesicular monoamine transporter (SLC18A2), genes in pathways implicated in human anxiety (HTR7, TDO2, and the endozepine-related protein precursor, DKFZP434A2417), and the micro 1-opioid receptor (OPRM1).
|
15048644 |
2004 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
It is suggested that NPY may influence ethanol consumption by regulating basal levels of anxiety, by modulating the sedative effects of ethanol, and/or by modulating ethanol's rewarding properties.
|
15337375 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) is a major endogenous regulator of anxiety-related behaviors and emotionality.
|
15897713 |
2005 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) was shown to modulate anxiety- and depression-related behaviors in various animal models.
|
16691011 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
For example, NPY is consistently involved in anxiety-related behaviors and there is increasing support for a role of this peptide in mood disorders such as depression.
|
16611091 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Since the neuropeptide Y (NPY) system has been reported to be involved in the pathophysiology of anxiety and in particular panic disorder and the genes coding for NPY Y1, Y2, and Y5 receptors are located in the suggested risk region (4q31-q32), variants in the NPY, NPY Y1, Y2, and Y5 genes were investigated for association with panic disorder in a sample of 230 German patients with panic disorder and matched healthy controls.
|
17948870 |
2008 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
There is extensive evidence, from both clinical cases and rodent models, for reduced levels of the widely expressed neuropeptide Y (NPY) in anxiety and depressive disorders.
|
19264362 |
2009 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we show that the claims of Zhou et al. that neuropeptide Y (NPY) diplotype-predicted expression is correlated with trait anxiety (neuroticism) is not replicated in a data set consisting of phenotypically extreme individuals drawn from a large (n = 88,142) non-clinical population.
|
19340021 |
2009 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) has been found to play a role in the pathomechanism of both anxiety and depression.
|
19854625 |
2010 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A recent study found NPY expression to be inversely correlated with trait anxiety.
|
20037921 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This differential genetic modulation of NPY stress response was suppressed in the SD group, who showed no stress-related increases in NPY and higher heart rate and greater anxiety, regardless of diplotype.
|
21917383 |
2012 |
|
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, we provide further support for involvement of mainly GAD1, but also NPY in determining predisposition to anxiety disorders.
|
22328461 |
2012 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
CCK interacts with several anxiety-relevant neurotransmitters such as the serotonergic, GABA-ergic and noradrenergic system as well as with endocannabinoids, NPY and NPS.
|
22553078 |
2012 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NPY has been attributed a central role in anxiety-like behavior, fear, nociception, and reward in rodents.
|
22938859 |
2012 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, alterations in anxiety- and depression-regulating genes were present in the hypothalamus of BACHD mice including reduced mRNA expression of neuropeptide Y, tachykinin receptor 3 and vesicular monoamine transporter type 2 as well as increased expression of cocaine and amphetamine regulated transcript.
|
23697793 |
2013 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NPY has recently gained much attention as an endogenous antiepileptic and antidepressant agent, as drugs with antiepileptic and/or mood-stabilizing properties may exert their action by increasing NPY concentrations, which in turn can reduce anxiety and depression levels, dampen seizures or increase seizure threshold.
|
23994577 |
2013 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Galanin (GAL) and neuropeptide Y (NPY) are neuropeptides involved in behaviors associated with anxiety.
|
24841617 |
2015 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we present an overview of findings with regard to the NPY system in relation to anxiety and stress, acute as well as chronic; furthermore we discuss post-traumatic stress disorder and, in part depression.
|
28824541 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Several reports have demonstrated that neuropeptide Y (NPY) is involved in food intake, epilepsy, circadian rhythms, drug seeking, pain and anxiety, and other physiological or pathological conditions.
|
29042065 |
2017 |